All News

A new formulation of the widely prescribed painkiller OxyContin has led drug abusers to shift to heroin, according to research results reported as a letter to the editor in the July 12 issue of the New England Journal of Medicine.

FDA has approved ziv-aflibercept (Zaltrap, Sanofi and Regeneron Pharmaceuticals) injection for intravenous infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.

FDA has announced a safety communication regarding the risk of seizures in patients with multiple sclerosis starting dalfampridine (Ampyra, Acorda Therapeutics). The safety communication stemmed from a review of post-marketing adverse event reports.

At a hearing held last week about the prescription drug gray market, John Coster, PhD, RPh, senior vice president of government affairs, National Community Pharmacists Association, testified that a balanced approach was necessary to address the prescription drug shortage problem and to protect patient care.

The Two Sister Study, funded in part by Susan Komen for the Cure, was conducted to examine the possible risks associated with fertility drugs and breast cancer. The results were published July 6 in the Journal of The National Cancer Institute.